Trial
NCT05895201
High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of GVHD
Phase IWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
Indiana University
Collaborators
—
Condition
Bone Marrow Transplant Complications
Intervention
Sitagliptin
Why stopped
PI has left IU with no plan to initiate study at IU
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-04-29